Yao J, et al. - Researchers report the management of a case of metastatic adenocarcinoma of unknown primary coexisting with long-term hypertension and renal cysts in an elderly man harboring mesenchymal-epithelial transition factor (MET) gene amplification and neurotrophic tyrosine receptor kinase 1 gene co-occurring mutation as revealed via targeted next-generation sequencing analysis upon the progression of empirical chemotherapy. After 1 month of treatment with a standard dose of crizotinib (250 mg, twice daily), a satisfactory complete response of the targeted lesions was noted. This case report indicates the possible promising efficacy of treatments based on driver genes rather than primary tumor types for obtaining better treatment outcome. Also, findings are suggestive of possible efficacy as well as tolerability of a half-dose of crizotinib for MET-overexpressed carcinomas of unknown primary with underlying renal diseases.